
Fikret Keles,1 Alp Yildirim,1 Ahmet Ridvan Bilgic,2 Muzeyyen Gizem Parmak,1 Mustafa Celik,3 Muhammet Salih Ates,1 Erdogan Sokmen1 1Department of Cardiology, Kirsehir Ahi Evran University Faculty of Medicine, Kirsehir, Turkiye; 2Department of Chest Diseases, Kirsehir Training and Research Hospital, Kirsehir, Turkiye; 3Department of Cardiology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, TurkiyeCorrespondence: Fikret Keles, Department of Cardiology, Kirsehir Ahi Evran University Faculty of Medicine, Medrese Mahallesi, Terme Caddesi, No: 47, Merkez/Kırşehir, 40100, Turkiye, Tel +90-530-294-64-90, Email keles.fikret@gmail.comBackground: Loss of the normal nocturnal blood pressure fall is an adverse circadian phenotype associated with heightened cardiovascular morbidity. This pattern is particularly prevalent in type 2 diabetes mellitus (T2DM), where endothelial impairment, microvascular injury, and autonomic dysregulation frequently coexist. The Endothelial Activation and Stress Index (EASIX), calculated from lactate dehydrogenase (LDH), creatinine, and platelet count, is an accessible laboratory composite integrating cellular injury, renal function, and platelet-related vascular information.Methods: This retrospective observational analysis screened consecutive patients with T2DM who underwent 24-hour ambulatory blood pressure monitoring (ABPM) between December 2024 and April 2026. After applying predefined eligibility criteria, 380 participants were included: 127 patients with non-dipper hypertension, 127 with dipper hypertension, and 126 normotensive diabetic controls. EASIX was calculated as (LDH × creatinine) / platelet count and transformed using the base-2 logarithm. Statistical analyses included Dunn-Bonferroni post-hoc pairwise comparisons, multivariable logistic regression, sensitivity modeling excluding nocturnal blood pressure, incremental discrimination assessment (ΔAUC, net reclassification improvement [NRI], integrated discrimination improvement [IDI]), ROC analysis, bootstrap internal validation, and decision curve analysis.Results: EASIX and log2(EASIX) were significantly elevated in non-dipper hypertensive patients compared with both dipper hypertensive patients (post-hoc adjusted p < 0.001) and normotensive diabetic controls (post-hoc adjusted p < 0.001). In multivariable logistic regression, log2(EASIX) independently predicted non-dipper status after adjusting for age, sex, BMI, HbA1c, absolute nighttime systolic blood pressure, smoking, and coronary artery disease (adjusted OR: 5.864, 95% CI: 3.182– 10.809, p < 0.001). In a sensitivity model excluding nighttime systolic blood pressure to prevent potential structural dependence, log2(EASIX) remained an independent predictor (adjusted OR: 5.412, 95% CI: 2.998– 9.768, p < 0.001). Adding log2(EASIX) to a baseline clinical model significantly improved discriminative performance (AUC increased from 0.612 to 0.751, ΔAUC = +0.139, p < 0.001), with a continuous NRI of 0.584 (p < 0.001) and an IDI of 0.142 (p < 0.001).Conclusion: In patients with T2DM and newly diagnosed hypertension, elevated EASIX is independently associated with the non-dipper blood pressure pattern and provides incremental predictive value beyond conventional clinical factors. EASIX represents an inexpensive, readily obtainable laboratory composite that may assist in the early risk stratification of diabetic patients requiring detailed ambulatory blood pressure assessment.Keywords: ambulatory blood pressure monitoring, endothelial dysfunction, EASIX, non-dipper hypertension, type 2 diabetes mellitus
Andrea Marani,1 Helena Gioacchini,2 Edvige Morea,3 Federica Tugnoli,4 Davide Bertolla,4,5 Sofia Spagnolini,5 Andrea Conti,1 Alfredo Giacchetti,2 Alessandro Borghi,4 Giulio Gualdi,5 Paolo Amerio,3 Anna Campanati6 1Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini, Italy; 2Dermatology Unit, INRCA/IRCCS, Ancona, Italy; 3Clinic of Dermatology, Department of Medicine and Aging Sciences, University G. d’Annunzio, Chieti, Italy; 4Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 5Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy; 6Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, ItalyCorrespondence: Anna Campanati, Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Via Conca 71, Ancona, 60126, Italy, Email anna.campanati@gmail.comAbstract: Disease modification (DM), a concept originating in rheumatology, has recently emerged as a therapeutic goal in dermatology, shifting the management of chronic inflammatory skin diseases away from a traditional “control-and-clear” approach toward altering the long-term disease course. However, no unified definition exists, and its meaning necessarily varies with disease biology. This narrative review, based on a structured literature search following SANRA guidance, appraises DM across seven cutaneous immune-mediated inflammatory diseases (IMIDs)—atopic dermatitis, vitiligo, hidradenitis suppurativa, alopecia areata, autoimmune bullous diseases, chronic spontaneous urticaria, and psoriasis—using explicit criteria and a uniform evidence-grading scale. In conditions causing irreversible structural damage—dermal tunnels and fibrosis in hidradenitis suppurativa, progression to psoriatic arthritis, and scarring in bullous diseases—DM aims chiefly to prevent cumulative tissue injury through early, sustained inflammatory control. In diseases without permanent damage, it is better defined by sustained treatment-free remission, relapse prevention, and restoration of immune homeostasis. Rituximab in pemphigus vulgaris is currently the only therapy convincingly fulfilling stringent DM criteria, through durable treatment-free remission and immune remodeling. Psoriasis represents the most advanced model, with IL-23p19 inhibition showing the most consistent evidence and IL-17 inhibition showing emerging signals; dupilumab offers the strongest support in atopic dermatitis, IL-17 inhibition provides the most robust disease control in hidradenitis suppurativa, without demonstrated treatment-free remission, whereas JAK inhibitors in vitiligo and alopecia areata remain disease-controlling. A recurring theme is the therapeutic window of opportunity, which remains a hypothesis, as no trial has randomized early versus delayed initiation of the same therapy. Persistent tissue-resident memory T cells, insufficient regulatory control, and residual molecular scars remain key barriers. We propose minimum trial-design features—randomized withdrawal, off-treatment endpoints, paired tissue sampling, and long-term follow-up—to demonstrate DM.Keywords: disease modification, immune-mediated inflammatory diseases, psoriasis, atopic dermatitis, inflammatory memory, window of opportunity
Xun Sun,1 Rongxia Sang,2 Tianyi Wang,1 Wei Li,3 Yusheng Li2 1Department of Respiratory and Critical Care Medicine, Bethune International Peace Hospital, Shijiazhuang, Hebei, 050051, People’s Republic of China; 2Department of Gastroenterology, Shijiazhuang People’s Hospital, Shijiazhuang, Hebei, 050000, People’s Republic of China; 3Department of Laboratory Medicine, Bethune International Peace Hospital, Shijiazhuang, Hebei, 050051, People’s Republic of ChinaCorrespondence: Xun Sun, Department of Respiratory and Critical Care Medicine, Bethune International Peace Hospital, Shijiazhuang, Hebei, 050051, People’s Republic of China, Email sunx_9537sx@outlook.comObjective: To investigate the association of serum mast cell-expressed membrane protein 1 (MCEMP1) levels with disease severity and 28-day mortality in patients with bacterial pneumonia, and to evaluate its clinical value as a biomarker.Methods: Bioinformatic analysis was performed using the GSE40012 dataset from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes between patients with bacterial pneumonia and healthy controls, which led to the selection of MCEMP1 as the candidate molecule. This prospective study enrolled 250 patients from May 2025 to January 2026. Serum MCEMP1 was measured by ELISA within 24 hours of admission and before the initiation of antibiotic therapy. Patients were stratified by Pneumonia Severity Index (PSI) into mild-to-moderate (n=118) and severe (n=132) groups, and by 28-day outcome into survivor (n=217) and non-survivor (n=33) groups. Spearman correlation analysis was used to evaluate the association between MCEMP1 and the PSI score. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive value of MCEMP1 for severe pneumonia and 28-day mortality. Multivariable logistic regression and Cox proportional hazards regression were used to identify factors independently associated with the occurrence of severe pneumonia and 28-day mortality, respectively. Survival curves were plotted using the Kaplan-Meier method, and between-group survival differences were compared using the Log rank test. The incremental predictive value of MCEMP1 beyond the PSI and Sequential Organ Failure Assessment (SOFA) scores was evaluated using DeLong test, the net reclassification improvement (NRI), and the integrated discrimination improvement (IDI), with internal validation performed using the bootstrap method.Results: Serum MCEMP1 levels were elevated in severe versus mild-to-moderate pneumonia (6.76± 1.18 vs 5.81± 1.07 ng/mL, P < 0.001) and correlated positively with the PSI score (r=0.381, P < 0.001). ROC curve analysis showed that serum MCEMP1 had moderate discriminatory ability for severe pneumonia (area under the curve [AUC] = 0.719), with an optimal cutoff value of 6.565 ng/mL (identified by exploratory analysis in the present cohort), yielding a sensitivity of 56.82% and a specificity of 77.12%. Serum MCEMP1 levels were also higher in non-survivors than survivors (7.94± 0.91 vs 6.06± 1.07 ng/mL, P < 0.001). For 28-day mortality, the AUC was 0.909 (95% CI: 0.853– 0.966), with an optimal cutoff value of 7.315 ng/mL (identified by exploratory analysis in the present cohort), yielding a sensitivity of 87.88% and a specificity of 86.18%. Multivariable logistic regression identified MCEMP1 (OR=2.204, 95% CI: 1.516– 3.205, P < 0.001), SOFA score (OR=2.577, P < 0.001), and procalcitonin (PCT) (OR=3.209, P = 0.016) as independently associated with the occurrence of severe pneumonia, whereas albumin was independently associated with a reduced risk of severe pneumonia (OR=0.763, P < 0.001). Kaplan-Meier analysis showed lower 28-day survival in the high-MCEMP1 group (> 7.315 ng/mL; log-rank χ2=106.50, P < 0.001). Multivariable Cox regression identified MCEMP1 (HR=4.032, 95% CI: 2.606– 6.239, P < 0.001), PSI score (HR=1.042, P = 0.006), and SOFA score (HR=1.283, P = 0.005) as independently associated with 28-day mortality. Incremental predictive value analysis showed that adding MCEMP1 to the baseline model comprising the PSI and SOFA scores (AUC = 0.773) improved the AUC for predicting 28-day mortality to 0.935 (ΔAUC = 0.162, DeLong test P < 0.001), with a continuous net reclassification improvement (NRI) of 1.310 (bootstrap 95% CI: 1.021– 1.627) and an integrated discrimination improvement (IDI) of 0.345 (bootstrap 95% CI: 0.208– 0.501). Bootstrap internal validation showed an optimism-corrected AUC of 0.928 for the combined model, indicating limited overfitting.Conclusion: Serum MCEMP1 was associated with disease severity and 28-day mortality in patients with bacterial pneumonia and was independently associated with the occurrence of severe pneumonia and 28-day mortality. Beyond existing clinical scores such as PSI and SOFA, MCEMP1 provided significant incremental prognostic information and showed promise as a candidate prognostic biomarker in the present cohort. As these findings are exploratory, independent external validation and longitudinal studies are needed before clinical application.Keywords: MCEMP1, bacterial pneumonia, disease severity, 28-day prognosis, biomarker
Xinxin Liu,1 Xiaohui Zou,2 Zhiyuan You1 1Shouguang Hospital of Traditional Chinese Medicine, Weifang, Shandong, People’s Republic of China; 2Shouguang People’s Hospital, Weifang, Shandong, People’s Republic of ChinaCorrespondence: Zhiyuan You, Shouguang Hospital of Traditional Chinese Medicine, Weifang, Shandong, People’s Republic of China, Email 395727202@qq.com
Wenbo Xu, Jintao Liu Department of Cardiology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, 314000, People’s Republic of ChinaCorrespondence: Wenbo Xu, Department of Cardiology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, 314000, People’s Republic of China, Email xuwenbo1984@126.comAbstract: Ventricular arrhythmias (VA) and sudden cardiac death (SCD) remain leading causes of mortality after myocardial infarction (MI). The conventional fibrosis-centric paradigm explains chronic reentrant VAs but cannot fully account for electrical instability in acute and subacute post-MI phases, highlighting an unmet need for upstream therapies targeting the arrhythmogenic substrate. Accumulating preclinical mechanistic and observational clinical evidence indicates that the inflammatory microenvironment in the infarct border zone may function as a critical upstream driver of electrical remodeling, mediated by neutrophils, macrophages and key pro-inflammatory cytokines (interleukin-1 beta (IL-1β), tumor necrosis factor-α (TNF-α)), constituting an inflammation-electrical remodeling axis that contributes to VA susceptibility across all post-MI stages. While causal relationships have been established in animal models, direct confirmation in human myocardium remains limited. This narrative review synthesizes preclinical and clinical evidence on this axis. It summarizes its spatiotemporal dynamics, four core cellular and molecular mechanisms and the antiarrhythmic potential of diverse anti-inflammatory interventions. We further outline key evidence gaps and translational directions, including precision risk stratification and cell-type-specific targeted delivery. Based on preclinical and preliminary clinical evidence, targeting the inflammation-electrical remodeling axis represents a promising upstream strategy to reduce post-MI SCD by addressing the root causes of electrical instability, though definitive proof of efficacy in humans is pending, and dedicated randomized controlled trials with arrhythmia endpoints are still required for clinical validation.Keywords: myocardial infarction, ventricular arrhythmias, infarct border zone, inflammation-electrical remodeling axis, anti-inflammatory therapy